Hidradenitis Suppurativa Clinical Trial
Official title:
Development and Maintenance of a National Registry For Patients With Hidradenitis Suppurativa
Verified date | March 2023 |
Source | Montefiore Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The goal of this study is to get a better understanding of the skin condition, Hidradenitis Suppurativa, and to find out how the disease affects quality of life. The investigators hope this information will help improve treatment for this skin condition.
Status | Completed |
Enrollment | 400 |
Est. completion date | September 6, 2022 |
Est. primary completion date | September 6, 2022 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Subjects 18-99 years of age who have a diagnosis of Hidradenitis Suppurativa (as deemed by a physician at the Montefiore Hidradenitis Suppurativa Treatment Center) Exclusion Criteria: - Patients without a diagnosis of Hidradenitis Suppurativa or under the age of 18 - Patients who are unable to answer given questions within the 6 surveys - Patient who are unable to be clinically evaluated by a Montefiore physician |
Country | Name | City | State |
---|---|---|---|
United States | Montefiore Medical Center | Bronx | New York |
Lead Sponsor | Collaborator |
---|---|
Montefiore Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Skin-related quality of life | Quality of life as measured using standardized Dermatology Quality of Life Index | Baseline | |
Primary | Presence and severity of depression | Presence and severity of depression as measured using standardized Beck Depression Inventory | Baseline | |
Primary | Skin-related of life | Quality of life as measured using standardized SkinDex questionnaires | Baseline | |
Primary | Subject-reported subject health | Subject-reported subject health as measured using the standardized SF-36 questionnaires | Baseline | |
Primary | Degree of enjoyment and satisfaction experienced by subjects in daily functioning. | Degree of enjoyment and satisfaction experienced by subjects in various areas of daily functioning as measured by the standardized Quality of Life Enjoyment and Satisfaction Questionnaire-short form. | Baseline | |
Primary | Employment and economic productivity | Self-reported employment and economic productivity as measured by a standardized health economic questionnaire | Baseline | |
Secondary | Change in quality of life | Change in quality of life as measured using standardized Dermatology Quality of Life Index after treatment initiation | At 6 months | |
Secondary | Change in presence and severity of depression | Change in presence and severity of depression as measured using standardized Beck Depression Inventory after treatment initiation | At 6 months | |
Secondary | Change in quality of life | Change in quality of life as measured using standardized SkinDex questionnaires after treatment initiation | At 6 months | |
Secondary | Change in subject-reported subject health | Change in subject-reported subject health as measured using standardized SF-36 questionnaires after treatment initiation | At 6 months | |
Secondary | Change in degree of enjoyment and satisfaction experienced by subjects in various areas of daily functioning | Change in degree of enjoyment and satisfaction experienced by subjects in various areas of daily functioning as measured by the standardized Quality of Life Enjoyment and Satisfaction Questionnaire-short form after treatment initiation | At 6 months | |
Secondary | Change in self-reported employment and economic productivity | Change in self-reported employment and economic productivity as measured by a standardized health economic questionnaire after treatment initiation | At 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02904902 -
Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa
|
Phase 3 | |
Completed |
NCT03628924 -
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
|
Phase 2 | |
Not yet recruiting |
NCT05531747 -
Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa
|
N/A | |
Recruiting |
NCT06028230 -
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
|
Phase 2 | |
Completed |
NCT03275870 -
Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
|
Phase 1/Phase 2 | |
Completed |
NCT03248531 -
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
|
Phase 2 | |
Withdrawn |
NCT04100083 -
Spironolactone for Hidradenitis Suppurativa
|
Phase 4 | |
Completed |
NCT00329823 -
Etanercept in Hidradenitis Suppurativa
|
Phase 2 | |
Recruiting |
NCT05710393 -
Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
|
||
Completed |
NCT04019041 -
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
|
Phase 2 | |
Completed |
NCT05286567 -
A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.
|
Phase 1 | |
Withdrawn |
NCT03929835 -
Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa
|
Phase 2 | |
Terminated |
NCT04325607 -
Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa
|
N/A | |
Terminated |
NCT03238469 -
Microwave Ablation in Mild Axillary Hidradenitis Suppurativa
|
N/A | |
Completed |
NCT04449354 -
HidraWear AX HS Study
|
N/A | |
Recruiting |
NCT06123429 -
Mindfulness in Hidradenitis Suppurativa
|
N/A | |
Recruiting |
NCT05934825 -
Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa
|
Phase 1/Phase 2 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Recruiting |
NCT06046729 -
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
|
Phase 2 | |
Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 |